Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...